Dr. Reddy’s Expands into Vietnam with New Subsidiary

Dr Reddy’s Laboratories ( (RDY) ) has issued an update.

On May 9, 2025, Dr. Reddy’s Laboratories SA, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited, incorporated a new wholly-owned subsidiary in Vietnam named Dr. Reddy’s Laboratories (Vietnam) Company Limited. This strategic move aligns with the company’s core business in healthcare and pharmaceuticals, expanding its market presence in Vietnam. The new subsidiary is expected to enhance the company’s operational capabilities and market reach in the region, although it is yet to commence business operations.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical and healthcare industry, primarily focusing on the development and marketing of healthcare and pharmaceutical products. The company is also involved in the sales and promotion of medical devices, with a strong emphasis on marketing and consulting services related to these products.

Average Trading Volume: 2,157,442

Technical Sentiment Signal: Sell

Current Market Cap: $11.26B

For an in-depth examination of RDY stock, go to TipRanks’ Stock Analysis page.